Boston Scientific invests $1.5bn for equity stake in MiRus
Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones.
19 May 2026
19 May 2026
Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3bn after achieving certain milestones.
Triveni Bio’s lead programme, TRIV-509, is in Phase II trial for atopic dermatitis, with results expected by 2026-end.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.